Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Capital International Sarl

Capital International Sarl boosted its holdings in Grifols, S.A. (NASDAQ:GRFS) by 11.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 388,824 shares of the biotechnology company’s stock after buying an additional 38,818 shares during the quarter. Capital International Sarl’s holdings in Grifols were worth $4,495,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Brandes Investment Partners LP lifted its position in shares of Grifols by 22.2% during the 4th quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock worth $156,245,000 after buying an additional 2,454,730 shares during the last quarter. Black Creek Investment Management Inc. lifted its position in Grifols by 16.4% in the third quarter. Black Creek Investment Management Inc. now owns 9,574,388 shares of the biotechnology company’s stock valued at $87,510,000 after acquiring an additional 1,351,000 shares during the last quarter. First Trust Advisors LP boosted its stake in Grifols by 6.9% in the fourth quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock valued at $54,156,000 after acquiring an additional 302,380 shares in the last quarter. Norges Bank purchased a new position in shares of Grifols during the fourth quarter worth about $26,137,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Grifols by 38.5% during the fourth quarter. New York State Common Retirement Fund now owns 2,058,286 shares of the biotechnology company’s stock worth $23,794,000 after purchasing an additional 572,439 shares during the last quarter.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft cut Grifols from a “hold” rating to a “sell” rating in a research report on Tuesday, March 12th.

Grifols Price Performance

GRFS stock traded down $0.03 on Wednesday, hitting $7.34. The company’s stock had a trading volume of 367,553 shares, compared to its average volume of 2,450,540. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The company has a quick ratio of 1.29, a current ratio of 2.79 and a debt-to-equity ratio of 1.26. The firm has a 50 day moving average of $6.92 and a two-hundred day moving average of $8.03.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.